These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 34917077)
21. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
22. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226 [TBL] [Abstract][Full Text] [Related]
23. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development. Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY Front Genet; 2022; 13():853113. PubMed ID: 35734437 [No Abstract] [Full Text] [Related]
24. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Guo L; Li X; Liu R; Chen Y; Ren C; Du S Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817 [TBL] [Abstract][Full Text] [Related]
25. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. Lu TL; Li CL; Gong YQ; Hou FT; Chen CW World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406 [TBL] [Abstract][Full Text] [Related]
27. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567 [TBL] [Abstract][Full Text] [Related]
28. The screening of immune-related biomarkers for prognosis of lung adenocarcinoma. Liu Z; Sun D; Zhu Q; Liu X Bioengineered; 2021 Dec; 12(1):1273-1285. PubMed ID: 33870858 [TBL] [Abstract][Full Text] [Related]
29. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q J Big Data; 2022; 9(1):92. PubMed ID: 35855914 [TBL] [Abstract][Full Text] [Related]
30. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma. Zou X; Hu Z; Huang C; Chang J Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949 [TBL] [Abstract][Full Text] [Related]
31. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development. Chen Z; Wang X; Yan Z; Zhang M Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582 [TBL] [Abstract][Full Text] [Related]
32. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients. Liu J; Wu H; Gao Z; Lou M; Yuan K Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805 [TBL] [Abstract][Full Text] [Related]
33. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
34. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Mao S; Li Y; Lu Z; Che Y; Huang J; Lei Y; Wang Y; Wang X; Liu C; Zheng S; Li N; Li J; Sun N; He J Cell Oncol (Dordr); 2020 Aug; 43(4):681-694. PubMed ID: 32462608 [TBL] [Abstract][Full Text] [Related]
35. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma. Wei S; Sun Q; Chen J; Li X; Hu Z Front Genet; 2022; 13():1068112. PubMed ID: 36579327 [No Abstract] [Full Text] [Related]
36. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584 [TBL] [Abstract][Full Text] [Related]
37. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma. Zhuang H; Tang C; Lin H; Zhang Z; Chen X; Wang W; Wang Q; Tan W; Yang L; Xie Z; Wang B; Chen B; Shang C; Chen Y Cell Oncol (Dordr); 2024 Aug; 47(4):1205-1220. PubMed ID: 38315287 [TBL] [Abstract][Full Text] [Related]
38. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
39. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. Wu P; Zheng Y; Wang Y; Wang Y; Liang N J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329 [TBL] [Abstract][Full Text] [Related]
40. Identification of a Five Autophagy Subtype-Related Gene Expression Pattern for Improving the Prognosis of Lung Adenocarcinoma. Zhang MY; Huo C; Liu JY; Shi ZE; Zhang WD; Qu JJ; Yue YL; Qu YQ Front Cell Dev Biol; 2021; 9():756911. PubMed ID: 34869345 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]